JP2013523772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523772A5 JP2013523772A5 JP2013502886A JP2013502886A JP2013523772A5 JP 2013523772 A5 JP2013523772 A5 JP 2013523772A5 JP 2013502886 A JP2013502886 A JP 2013502886A JP 2013502886 A JP2013502886 A JP 2013502886A JP 2013523772 A5 JP2013523772 A5 JP 2013523772A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- biocompatible polymer
- fluid
- polymer
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 229920000249 biocompatible polymer Polymers 0.000 claims 18
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 12
- 239000012530 fluid Substances 0.000 claims 11
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 claims 10
- 239000011148 porous material Substances 0.000 claims 10
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical group C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 8
- 229920001577 copolymer Polymers 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 7
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims 6
- 239000003463 adsorbent Substances 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 239000011236 particulate material Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000843 powder Substances 0.000 claims 5
- CQHKDHVZYZUZMJ-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-prop-2-enoyloxypropyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(CO)COC(=O)C=C CQHKDHVZYZUZMJ-UHFFFAOYSA-N 0.000 claims 3
- 239000003431 cross linking reagent Substances 0.000 claims 3
- 239000002270 dispersing agent Substances 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 239000002002 slurry Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- NWRZGFYWENINNX-UHFFFAOYSA-N 1,1,2-tris(ethenyl)cyclohexane Chemical compound C=CC1CCCCC1(C=C)C=C NWRZGFYWENINNX-UHFFFAOYSA-N 0.000 claims 2
- WVAFEFUPWRPQSY-UHFFFAOYSA-N 1,2,3-tris(ethenyl)benzene Chemical compound C=CC1=CC=CC(C=C)=C1C=C WVAFEFUPWRPQSY-UHFFFAOYSA-N 0.000 claims 2
- MYWOJODOMFBVCB-UHFFFAOYSA-N 1,2,6-trimethylphenanthrene Chemical compound CC1=CC=C2C3=CC(C)=CC=C3C=CC2=C1C MYWOJODOMFBVCB-UHFFFAOYSA-N 0.000 claims 2
- QLLUAUADIMPKIH-UHFFFAOYSA-N 1,2-bis(ethenyl)naphthalene Chemical compound C1=CC=CC2=C(C=C)C(C=C)=CC=C21 QLLUAUADIMPKIH-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 2
- 239000004793 Polystyrene Substances 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- GQPVFBDWIUVLHG-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(CO)COC(=O)C(C)=C GQPVFBDWIUVLHG-UHFFFAOYSA-N 0.000 claims 2
- JUDXBRVLWDGRBC-UHFFFAOYSA-N [2-(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)-2-(2-methylprop-2-enoyloxymethyl)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(COC(=O)C(C)=C)COC(=O)C(C)=C JUDXBRVLWDGRBC-UHFFFAOYSA-N 0.000 claims 2
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 claims 2
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 238000007265 chloromethylation reaction Methods 0.000 claims 2
- -1 complement Proteins 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- LKIPOGBWSIFYFM-UHFFFAOYSA-N n,n-bis(ethenyl)formamide Chemical compound C=CN(C=C)C=O LKIPOGBWSIFYFM-UHFFFAOYSA-N 0.000 claims 2
- 229920002223 polystyrene Polymers 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 238000009736 wetting Methods 0.000 claims 2
- ZZHIDJWUJRKHGX-UHFFFAOYSA-N 1,4-bis(chloromethyl)benzene Chemical compound ClCC1=CC=C(CCl)C=C1 ZZHIDJWUJRKHGX-UHFFFAOYSA-N 0.000 claims 1
- MHHJQVRGRPHIMR-UHFFFAOYSA-N 1-phenylprop-2-en-1-ol Chemical compound C=CC(O)C1=CC=CC=C1 MHHJQVRGRPHIMR-UHFFFAOYSA-N 0.000 claims 1
- IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 claims 1
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 claims 1
- QHVBLSNVXDSMEB-UHFFFAOYSA-N 2-(diethylamino)ethyl prop-2-enoate Chemical compound CCN(CC)CCOC(=O)C=C QHVBLSNVXDSMEB-UHFFFAOYSA-N 0.000 claims 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 claims 1
- ZTLUZWVSPCRCTC-UHFFFAOYSA-N 2-methylprop-2-enoic acid Chemical compound C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O ZTLUZWVSPCRCTC-UHFFFAOYSA-N 0.000 claims 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000003870 Drug Overdose Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical group CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 1
- 206010059399 Graft ischaemia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010022678 Intestinal infections Diseases 0.000 claims 1
- 102000002397 Kinins Human genes 0.000 claims 1
- 108010093008 Kinins Proteins 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010033296 Overdoses Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 229920001311 Poly(hydroxyethyl acrylate) Polymers 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 claims 1
- TUOBEAZXHLTYLF-UHFFFAOYSA-N [2-(hydroxymethyl)-2-(prop-2-enoyloxymethyl)butyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(CC)COC(=O)C=C TUOBEAZXHLTYLF-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003518 caustics Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 210000003756 cervix mucus Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920001688 coating polymer Polymers 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims 1
- 125000004386 diacrylate group Chemical group 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 231100000725 drug overdose Toxicity 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- ZNAOFAIBVOMLPV-UHFFFAOYSA-N hexadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(C)=C ZNAOFAIBVOMLPV-UHFFFAOYSA-N 0.000 claims 1
- PZDUWXKXFAIFOR-UHFFFAOYSA-N hexadecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C=C PZDUWXKXFAIFOR-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002977 intracellular fluid Anatomy 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 claims 1
- 230000009701 normal cell proliferation Effects 0.000 claims 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 claims 1
- 229940065472 octyl acrylate Drugs 0.000 claims 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31999310P | 2010-04-01 | 2010-04-01 | |
| US61/319,993 | 2010-04-01 | ||
| PCT/US2011/030919 WO2011123767A1 (en) | 2010-04-01 | 2011-04-01 | Method of treating inflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016079100A Division JP2016175914A (ja) | 2010-04-01 | 2016-04-11 | 炎症を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523772A JP2013523772A (ja) | 2013-06-17 |
| JP2013523772A5 true JP2013523772A5 (enExample) | 2014-05-01 |
| JP6073778B2 JP6073778B2 (ja) | 2017-02-01 |
Family
ID=44712650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502886A Active JP6073778B2 (ja) | 2010-04-01 | 2011-04-01 | 炎症を治療する方法 |
| JP2016079100A Pending JP2016175914A (ja) | 2010-04-01 | 2016-04-11 | 炎症を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016079100A Pending JP2016175914A (ja) | 2010-04-01 | 2016-04-11 | 炎症を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9717755B2 (enExample) |
| EP (2) | EP3384916A1 (enExample) |
| JP (2) | JP6073778B2 (enExample) |
| CN (2) | CN107260755A (enExample) |
| AU (1) | AU2011234978B2 (enExample) |
| CA (1) | CA2795177C (enExample) |
| ES (1) | ES2686545T3 (enExample) |
| MX (1) | MX342421B (enExample) |
| WO (1) | WO2011123767A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3384916A1 (en) * | 2010-04-01 | 2018-10-10 | Cytosorbents Corporation | Sorbent for treating inflammation |
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| CN103619372A (zh) | 2011-03-23 | 2014-03-05 | 纳科斯达格医药股份有限公司 | 腹膜透析系统、装置和方法 |
| EP2679302A1 (de) | 2012-06-28 | 2014-01-01 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Selektives Sorptionsmittel für die extrakorporale Blutreinigung |
| EP3673930B1 (en) * | 2012-06-29 | 2024-10-30 | Cytosorbents Corporation | Biocompatible sorbent |
| CN106457205B (zh) * | 2014-07-22 | 2020-09-22 | 旭化成医疗株式会社 | 去除组蛋白的吸附材料和生物来源液体净化设备 |
| CN114306208A (zh) * | 2014-10-02 | 2022-04-12 | 西托索尔本茨公司 | 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途 |
| RU2018134142A (ru) * | 2016-03-08 | 2020-04-08 | Сайтосорбентс Корпорейшн | Применение гранулированного сорбента на основе гемосовместимого пористого полимера для удаления молекулярных структур, ассоциированных с патогенами, и молекулярных структур, ассоциированных с повреждениями |
| CN109562353B (zh) * | 2016-05-26 | 2022-07-15 | 西托索尔本茨公司 | 使用血液相容性多孔聚合物珠吸着剂去除内毒素血症诱导分子 |
| AU2018273348A1 (en) * | 2017-05-23 | 2019-11-21 | Cytosorbents Corporation | Method of treating traumatic brain injury |
| EP3641850B1 (en) | 2017-06-24 | 2024-10-09 | NxStage Medical Inc. | Peritoneal dialysis fluid preparation systems |
| RU2020111589A (ru) * | 2017-08-31 | 2021-09-30 | Сайтосорбентс Корпорейшн | Снижение уровня конечных продуктов глубокого гликирования из биологических жидкостей |
| CA3296263A1 (en) | 2018-02-28 | 2026-03-02 | Nxstage Medical, Inc. | Fluid preparation and treatment devices, methods, and systems |
| CA3118792A1 (en) * | 2018-11-16 | 2020-05-22 | Hemanext Inc. | Methods for managing adverse events in patients with inflammation |
| WO2021034773A1 (en) * | 2019-08-16 | 2021-02-25 | Cytosorbents Corporation | Methods for improving bone fracture healing |
| CN114502210B (zh) | 2019-09-30 | 2024-07-19 | 埃莫图内股份公司 | 用于体外治疗体液的组合件 |
| JP2023522621A (ja) * | 2020-04-14 | 2023-05-31 | サイトソーベンツ・コーポレーション | 免疫調整治療による免疫応答の改善と免疫麻痺の減少 |
| WO2022040431A1 (en) * | 2020-08-19 | 2022-02-24 | Cytosorbents Corporation | Therapeutic and cosmetic wound treatment |
| US20250009951A1 (en) * | 2021-11-29 | 2025-01-09 | Cytosorbents Corporation | Improved cancer immunotherapy treatments |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU213165B (en) * | 1993-05-11 | 1997-02-28 | Bot | Process to prepare biopolymers with detoxicating activity |
| US5904663A (en) | 1997-07-30 | 1999-05-18 | Braverman; Andrew | Method of removing beta-2 microglobulin from blood |
| US20020159995A1 (en) * | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
| US6416487B1 (en) | 1997-07-30 | 2002-07-09 | Renal Tech International Llc | Method of removing beta-2 microglobulin from blood |
| US20020197250A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
| JP2003523777A (ja) | 1998-01-06 | 2003-08-12 | シーラス コーポレイション | 細胞を含む生物学的組成物からの化合物の減少のためのバッチデバイスおよびその使用方法 |
| US20020197252A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
| US7651974B2 (en) * | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1547605B1 (en) | 2002-11-01 | 2008-08-20 | Kureha Corporation | Adsorbents for oral administration |
| TWI370012B (en) * | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US20050255048A1 (en) * | 2004-05-15 | 2005-11-17 | Collegium Pharmaceutical, Inc. | Sprayable formulations for the treatment of acute inflammatory skin conditions |
| US20060078534A1 (en) * | 2004-10-13 | 2006-04-13 | Dominique Charmot | Toxin binding compositions |
| EP1802349A1 (en) * | 2004-10-13 | 2007-07-04 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| US20060228416A1 (en) * | 2005-04-06 | 2006-10-12 | Marie-Pierre Faure | Methods for modulating topical inflammatory response |
| EP1842545A1 (en) * | 2006-04-04 | 2007-10-10 | Marinomed Biotechnologie GmbH | Anti-inflammatory polymer |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| US7875182B2 (en) * | 2006-11-20 | 2011-01-25 | Cytosorbents, Inc. | Size-selective hemoperfusion polymeric adsorbents |
| US20090130048A1 (en) * | 2007-11-19 | 2009-05-21 | Oronsky Bryan Todd | Topical Composition for Treating Pain |
| CN101307149B (zh) | 2008-05-30 | 2011-06-01 | 珠海健帆生物科技股份有限公司 | 一种医用吸附剂载体的制备方法 |
| ES2651948T3 (es) * | 2008-10-02 | 2018-01-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administración de un polímero adsorbente para el tratamiento de la inflamación sistémica |
| US8923172B2 (en) * | 2009-08-24 | 2014-12-30 | Qualcomm Incorporated | Deterministic backoff channel access |
| EP3384916A1 (en) * | 2010-04-01 | 2018-10-10 | Cytosorbents Corporation | Sorbent for treating inflammation |
| US10064406B2 (en) | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
-
2011
- 2011-04-01 EP EP18158174.5A patent/EP3384916A1/en not_active Withdrawn
- 2011-04-01 CN CN201710354912.2A patent/CN107260755A/zh active Pending
- 2011-04-01 CN CN201180027139XA patent/CN103037869A/zh active Pending
- 2011-04-01 CA CA2795177A patent/CA2795177C/en active Active
- 2011-04-01 WO PCT/US2011/030919 patent/WO2011123767A1/en not_active Ceased
- 2011-04-01 ES ES11763501.1T patent/ES2686545T3/es active Active
- 2011-04-01 AU AU2011234978A patent/AU2011234978B2/en active Active
- 2011-04-01 MX MX2012011305A patent/MX342421B/es active IP Right Grant
- 2011-04-01 US US13/637,775 patent/US9717755B2/en active Active
- 2011-04-01 JP JP2013502886A patent/JP6073778B2/ja active Active
- 2011-04-01 EP EP11763501.1A patent/EP2552459B1/en active Active
-
2016
- 2016-04-11 JP JP2016079100A patent/JP2016175914A/ja active Pending
- 2016-06-03 US US15/172,209 patent/US11058715B2/en active Active
-
2017
- 2017-06-28 US US15/635,517 patent/US10034894B2/en active Active
-
2018
- 2018-06-26 US US16/018,603 patent/US10967001B2/en active Active
-
2019
- 2019-05-29 US US16/424,747 patent/US10946040B2/en active Active
-
2021
- 2021-04-13 US US17/229,265 patent/US20210330697A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10946040B2 (en) | Method of treating inflammation | |
| JP6945607B2 (ja) | ポリマーの使用法 | |
| JP5670336B2 (ja) | 全身性炎症の治療のためのポリマー吸着剤の投与 | |
| JP7227192B2 (ja) | 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用 | |
| Joshi et al. | Medical applications of activated carbon | |
| EP4135749A1 (en) | Improved immune response and decreased immunoparalysis with immunomodulating treatment | |
| JP2020532417A (ja) | 体液からの終末糖化産物の削減 |